

CLAIMS:

1. Peptide having 13-55 amino acid residues characterized in that said peptide comprises the amino acid sequence

5

A G W L R₁ D R₂ R₃ R₄ R₅ Y P I

in which R₁ = A, S

R₂ = Q, R, G

10

R₃ = T, S

R₄ = V, L

R₅ = R, Q.

with the provision that the peptide is not SSAGWLADRSVRYPIISKARPNXGG,
NAGWLSGSGVQYPITKPREP, DAGWLADGHSVRYPIISRPRKR,
15 GGLDWCNAGWLSGSGVQYPITKPR or
EQLFAAYEDGFECQDAGWLADQTVRYPIRAPRVGCY.

2. Peptide having 13-55 amino acid residues characterized in that said peptide comprises at least the amino acid sequence

20

A G W L R₁ D R₂ R₃ L R₅ Y P I

in which R₁ = A, S

25

R₂ = Q, R, G

R₃ = T, S

R₅ = R, Q.

3. Peptide having 13-55 amino acid residues characterized in that said peptide comprises at least one of the amino acid sequences AGWLADQTVRYPI,
30 AGWLADRSVRYPI, AGWLSGSGVQYPI and AGWLADGSLRYPI.

4. Peptide consisting of one of the amino acid sequences AGWLADQTVRYPI, AGWLADRSVRYPI, AGWLSDGSVQYPI and AGWLADGSLRYPI.
5. Peptide having 13-55 amino acid residues and comprizing the amino acid sequence A G W L R₁ D R₂ R₃ R₄ R₅ Y P I in which R₁ = A, S, R₂ = Q, R, G, R₃ = T, S, R₄ = V, L, and R₅ = R, Q, for use as a medicament.
6. Pharmaceutical preparation comprizing a peptide having 13-55 amino acid residues, said peptide comprizing the amino acid sequence A G W L R₁ D R₂ R₃ R₄ R₅ Y P I in which R₁ = A, S, R₂ = Q, R, G, R₃ = T, S, R₄ = V, L, and R₅ = R, Q, and a pharmaceutical acceptable carrier.
7. Pharmaceutical preparation comprizing a peptide having 13-55 amino acid residues, said peptide comprizing the amino acid sequence A G W L R₁ D R₂ R₃ L R₅ Y P I in which R₁ = A, S, R₂ = Q, R, G, R₃ = T, S and R₅ = R, Q, and a pharmaceutical acceptable carrier.
8. Pharmaceutical preparation comprizing a peptide having 13-55 amino acid residues, said peptide comprizing at least one of the amino acid sequences AGWLADQTVRYPI, AGWLADRSVRYPI, AGWLSDGSVQYPI and AGWLADGSLRYPI.
9. Pharmaceutical preparation comprizing at least one of the peptides AGWLADQTVRYPI, AGWLADRSVRYPI, AGWLADGSLRYPI and AGWLSDGSVQYPI and a pharmaceutical acceptable carrier.
10. Use of a peptide having 13-55 amino acid residues, said peptide comprizing the amino acid sequence A G W L R₁ D R₂ R₃ R₄ R₅ Y P I in which R₁ = A, S, R₂ = Q, R, G, R₃ = T, S, R₄ = V, L, and R₅ = R, Q, for the manufacture of a pharmaceutical preparation for use in a peptide-induced tolerance therapy for the induction of tolerance to autoaggressive T cells associated with T-cell mediated articular cartilage destruction in autoimmune diseases.